Login to Your Account



Bristol-Myers Demands Changes In Erbitux Deal With ImClone

By Randall Osborne


Thursday, February 7, 2002
In a move that seemed to surprise few industry observers, Bristol-Myers Squibb Co. said it wants to restructure the potential $2 billion deal with ImClone Systems Inc. regarding the FDA-stalled Erbitux (cetuximab) for colorectal cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription